About the Authors

Zhu Luo

Affiliation Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

Feng Nan

Affiliation Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

Jia Miao

Affiliation Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

Zhihui Chen

Affiliation Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

Mei Li

Affiliation Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

Maozhi Liang

wchscu@sohu.com

Affiliation Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

Competing Interests

The study was funded by Beijing Furuikangzheng Pharmaceuticals Co. Ltd.(Beijing, People's Republic of China) and this company manufactures the febuxostat tablets tested in the trial. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: ZL M. Liang. Performed the experiments: FN ZC JM M. Li. Analyzed the data: ZL M. Liang. Contributed reagents/materials/analysis tools: FN ZC. Wrote the paper: ZL.